SMAD3 and polycystic ovary syndrome: As shown in Figure 10, the p‐Smad2 and p‐Smad3 levels in both the SA and Met treatments were significantly lower than those in the PCOS rats (p < .01), and the decrease in the SA‐treated PCOS rats was more pronounced than in the Met‐treated PCOS rats (p < .01).